Wells Fargo’s Kiora Pharmaceuticals KPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding KPRX
ACM
RA
NCM
SCM
ACM
VCIM
Wells Fargo's KPRX Position: Q2 2024 in Review
Wells Fargo sold out of Kiora Pharmaceuticals (KPRX) in Q2 2024, closing a stake of 7 shares — an estimated $42 sold.
Wells Fargo first reported a position in KPRX in Q3 2022 and held it in 7 quarters. The position peaked at $64 in Q3 2023. 17 funds tracked by Wall St. Rank hold KPRX as of Q2 2024.
- Wells Fargo reported no remaining Kiora Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 7 Kiora Pharmaceuticals shares in Q2 2024, an estimated $42.
- Wells Fargo first reported a position in Kiora Pharmaceuticals in Q3 2022 and held it in 7 quarters.
- Wells Fargo's Kiora Pharmaceuticals position peaked at $64 in Q3 2023.
- 17 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.